Technology ID
TAB-4970
Development of Messenger RNA (mRNA) Vaccines Targeting SARS-CoV-2 Antigens
E-Numbers
E-182-2020-0
Lead Inventor
Morabito, Kaitlyn
Lead IC
NIAID
Co-Inventors
Mascola, John
Graham, Barney
Hutchinson, Geoffrey
Corbett, Kizzmekia
Zamanda, Cynthia
Abiona, Olubukola
ICs
NIAID
Applications
Vaccines
Therapeutic Areas
Rare/Neglected Diseases
Infectious Disease
Development Stages
Clinical Phase I
Research Products
Research Equipment
Plasmids/Vectors
Human Cell Lines
Antibodies
Animal Models
The development of mRNA vaccines targeting SARS-CoV-2 antigens represents a groundbreaking advancement in vaccine technology. These vaccines, currently in Clinical Phase I, utilize messenger RNA to encode coronavirus antigens, triggering a potent immune response that includes the production of neutralizing antibodies. Unlike traditional vaccines, mRNA vaccines do not use live or inactivated viruses, which enhances safety and allows for rapid development. The use of a stabilized prefusion spike protein as a key antigen further enhances the vaccine's efficacy. This innovative approach not only holds promise for combatting COVID-19 but also paves the way for more efficient vaccine development against future infectious diseases.
Commercial Applications
The potential applications of mRNA vaccines targeting SARS-CoV-2 extend beyond the current COVID-19 pandemic. These vaccines represent a versatile platform that can be rapidly adapted to address emerging variants of the virus. Furthermore, the mRNA technology can be applied to develop vaccines against other infectious diseases, offering a more efficient and scalable approach compared to traditional methods. Additionally, mRNA vaccines have the potential to be used in cancer immunotherapy, where they can be tailored to target specific tumor antigens, offering a personalized treatment option. Moreover, the mRNA platform can be utilized for the development of prophylactic vaccines against a wide range of pathogens, providing a valuable tool in global health security efforts.
Competitive Advantages
This mRNA vaccine technology for SARS-CoV-2 offers several competitive advantages over traditional vaccine approaches. Firstly, its use of mRNA allows for a faster development timeline, critical in responding to rapidly evolving infectious diseases. Secondly, the vaccines do not contain any live virus, reducing the risk of adverse reactions and allowing for safer administration. Additionally, the ability to encode various coronavirus antigens, including the stabilized prefusion spike protein, enables a targeted and robust immune response. This targeted approach may result in higher efficacy rates compared to conventional vaccines. Furthermore, the mRNA platform is highly versatile, potentially allowing for the rapid adaptation of the vaccine to address new variants of the virus. These advantages position mRNA vaccines as a promising solution not only for the current COVID-19 pandemic but also for future infectious disease outbreaks.
Licensing Contact: